Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?

Eli Lilly has posted several sets of pivotal trial data portraying its dual-action drug candidate tirzepatide as a potentially better diabetes option than Novo Nordisk’s Ozempic. But those cross-trial comparisons made the argument less compelling, and industry watchers had been holding out for results from a head-to-head study.